Multi-center, Randomized, Double-blinded Assessment of Tecfidera in Extending the Time to a First Attack in Radiologically Isolated Syndrome (RIS) (ARISE)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 22 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Nov 2022 Primary endpoint (the time to onset of clinical symptoms attributable to a CNS demyelinating event within a follow-up period of 96 weeks ) has been met, according to Results published in the Annals of Neurology.
18 Nov 2022 Results published in the Annals of Neurology
26 Oct 2022 According to a Biogen media release, data from this study presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), will be presented in the late-breaking section

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com